1999 - Fellow of the American Association for the Advancement of Science (AAAS)
Member of the Association of American Physicians
Peter H. Schur spends much of his time researching Immunology, Antibody, Internal medicine, Lupus erythematosus and Antigen. Immunology is closely attributed to Disease in his work. His work in the fields of Antibody, such as Immunoglobulin G, Subclass and Gamma globulin, overlaps with other areas such as In patient.
His Internal medicine research includes themes of Gastroenterology, Endocrinology, Physical therapy and Cardiology. Peter H. Schur interconnects Glomerulonephritis, Nephrosis, Complement component 5, Complement components and Serum complement in the investigation of issues within Lupus erythematosus. His Antigen research includes elements of Bacterial polysaccharide, Monoclonal antibody and Microbiology.
Peter H. Schur mainly focuses on Immunology, Antibody, Internal medicine, Lupus erythematosus and Rheumatoid arthritis. His work on Antigen, Autoantibody and Anti-nuclear antibody as part of general Immunology study is frequently linked to In patient, bridging the gap between disciplines. His biological study deals with issues like Molecular biology, which deal with fields such as DNA.
The various areas that Peter H. Schur examines in his Internal medicine study include Gastroenterology, Endocrinology and Physical therapy. Peter H. Schur has included themes like Systemic disease, Restriction fragment length polymorphism and Anti-SSA/Ro autoantibodies in his Lupus erythematosus study. His Rheumatoid arthritis research incorporates elements of Juvenile rheumatoid arthritis, Arthritis and Autoimmunity.
Immunology, Internal medicine, Rheumatoid arthritis, Antibody and Systemic lupus erythematosus are his primary areas of study. His work carried out in the field of Immunology brings together such families of science as Dermatology, Disease and Medical record. Indirect immunofluorescence, Titer and Retrospective review is closely connected to Gastroenterology in his research, which is encompassed under the umbrella topic of Internal medicine.
His Rheumatoid arthritis research is multidisciplinary, incorporating perspectives in Autoantibody, Autoimmunity and Asthma. His work on Subclass and Immunoglobulin heavy chain as part of general Antibody study is frequently connected to Context and In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. The concepts of his Systemic lupus erythematosus study are interwoven with issues in Intensive care medicine, Vasculitis, Organ damage, Lupus nephritis and Mixed connective tissue disease.
Peter H. Schur focuses on Immunology, Internal medicine, Rheumatoid arthritis, Anti-nuclear antibody and Autoantibody. The study incorporates disciplines such as Dermatology and Lupus nephritis, Disease in addition to Immunology. His studies deal with areas such as Gastroenterology and Lupus erythematosus as well as Internal medicine.
Peter H. Schur combines subjects such as Proportional hazards model, Antibody, Multiplex and Arthritis with his study of Rheumatoid arthritis. The Immunoassay and Rheumatoid factor research he does as part of his general Antibody study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science. His Anti-nuclear antibody research is multidisciplinary, incorporating elements of Systemic lupus erythematosus and Fibromyalgia.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes
Matthew H. Liang;Michael Corzillius;Sang Cheol Bae;Robert A. Lew.
Arthritis & Rheumatism (1999)
IMMUNOLOGICAL STUDIES CONCERNING THE NEPHRITIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
David Koffler;Peter H. Schur;Henry G. Kunkel.
Journal of Experimental Medicine (1967)
Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus.
E M Tan;P H Schur;R I Carr;H G Kunkel.
Journal of Clinical Investigation (1966)
Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus
Matthew H. Liang;Steven A. Socher;Martin G. Larson;Peter H. Schur.
Arthritis & Rheumatism (1989)
Immunologic Factors and Clinical Activity in Systemic Lupus Erythematosus
Peter H. Schur;John Sandson.
The New England Journal of Medicine (1968)
Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis
Katherine S. Ginsburg;Matthew H. Liang;Laura Newcomer;Samuel Z. Goldhaber.
Annals of Internal Medicine (1992)
Correlation between Serum IgG-2 Concentrations and the Antibody Response to Bacterial Polysaccharide Antigens
George R. Siber;Peter H. Schur;Alan C. Aisenberg;Sigmund A. Weitzman.
The New England Journal of Medicine (1980)
Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease.
J Wu;J Wilson;J He;L Xiang.
Journal of Clinical Investigation (1996)
ANA screening: an old test with new recommendations
Pier Luigi Meroni;Peter H Schur.
Annals of the Rheumatic Diseases (2010)
Measurement of Serum DNA-Binding Activity in Systemic Lupus Erythematosus
Theodore Pincus;Peter H. Schur;James A. Rose;John L. Decker.
The New England Journal of Medicine (1969)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: